Phenotypes associated with this allele

• Allele Symbol: Irf4^tm1Mak
• Allele Name: targeted mutation 1, Tak Mak
• Allele ID: MGI:2387941
• Summary: 6 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Irf4^tm1Mak/Irf4^tm1Mak	B6.129P2-Irf4^tm1Mak	MGI:3584109
hm2	Irf4^tm1Mak/Irf4^tm1Mak	involves: 129P2/OlaHsd	MGI:3584108
hm3	Irf4^tm1Mak/Irf4^tm1Mak	involves: 129P2/OlaHsd * C57BL/6	MGI:3584110
cx4	Col1a1^tm1(tetO-Irf4)Sing/Col1a1^tm1(tetO-Irf4)Sing Gt(ROSA)26Sor^tm1(rtTA*M2)Jae/Gt(ROSA)26Sor^+ Irf4^tm1Mak/Irf4^+	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6	MGI:5529093
cx5	Col1a1^tm1(tetO-Irf4)Sing/Col1a1^tm1(tetO-Irf4)Sing Gt(ROSA)26Sor^tm1(rtTA*M2)Jae/Gt(ROSA)26Sor^+ Irf4^tm1Mak/Irf4^tm1Mak	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6	MGI:5529094
cx6	Irf8^tm1Hor/Irf8^tm1Hor Irf4^tm1Mak/Irf4^tm1Mak	involves: 129P2/OlaHsd * C57BL/6	MGI:3584112

Genotype
MGI:3584109

hm1

• Allelic Composition: Irf4^tm1Mak/Irf4^tm1Mak
• Genetic Background: B6.129P2-Irf4^tm1Mak

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

abnormal CD4-positive, alpha beta T cell morphology ( J:78909 )

• failed to produce Il4 or Ifn gamma after infection with Leishmania major

abnormal T-helper 1 cell differentiation ( J:78909 )

• defect in differentiation of Th1 cells

increased susceptibility to bacterial infection ( J:78909 )

• increased succeptibility to Leishmania infection

hematopoietic system

abnormal CD4-positive, alpha beta T cell morphology ( J:78909 )

• failed to produce Il4 or Ifn gamma after infection with Leishmania major

abnormal T-helper 1 cell differentiation ( J:78909 )

• defect in differentiation of Th1 cells

Genotype
MGI:3584108

hm2

• Allelic Composition: Irf4^tm1Mak/Irf4^tm1Mak
• Genetic Background: involves: 129P2/OlaHsd

cellular

decreased B cell proliferation ( J:42683 )

decreased T cell proliferation ( J:42683 )

• reduced T cell proliferation

immune system

immune system phenotype ( J:169863 )

N • mice exhibit normal thymic and splenic gamma-delta T17 cells

abnormal spleen morphology ( J:42683 )

enlarged spleen ( J:42683 )

• spleen enlarged 3-5X by 10-15 weeks of age

absent spleen germinal center ( J:42683 )

• absent germinal centers in B cell follicles of spleen

abnormal immune system cell morphology ( J:42683 )

abnormal B cell differentiation ( J:42683 )

• decreased membrane IgMIgD B cells

• increased membrane IgM IgD B cells

arrested B cell differentiation ( J:42683 )

• late stage B cell maturation blocked

decreased dendritic cell number ( J:91043 )

• proportion of dendritic cells in spleen 50% of controls but proportion as expected in thymus

• single (+) CD4 dendritic cells reduced to about 10% of control levels in the spleen

absent plasma cells ( J:42683 )

• no plasma cells in spleen or lamina propria

increased lymphocyte cell number ( J:42683 )

• normal lymphocyte distribution at 4-5 weeks of age

• expanded numbers of T and B lymphocytes at 10-15 weeks of age

abnormal lymph node morphology ( J:42683 )

absent lymph node germinal center ( J:42683 )

• absent germinal centers in B cell follicles of lymph nodes

enlarged lymph nodes ( J:42683 )

• enlarged 10X by 10-15 weeks of age

abnormal immune system physiology ( J:42683 )

decreased B cell proliferation ( J:42683 )

decreased T cell proliferation ( J:42683 )

• reduced T cell proliferation

decreased immunoglobulin level ( J:42683 )

• all immunoglobulin classes reduced by 99% or more

increased susceptibility to Riboviria infection ( J:42683 )

• no cytotoxic T cell response to lymphocytic choriomeningitis virus

neoplasm

abnormal tumor susceptibility ( J:42683 )

• unable to reject injected tumor cells

hematopoietic system

decreased B cell proliferation ( J:42683 )

decreased T cell proliferation ( J:42683 )

• reduced T cell proliferation

abnormal B cell differentiation ( J:42683 )

• decreased membrane IgMIgD B cells

• increased membrane IgM IgD B cells

arrested B cell differentiation ( J:42683 )

• late stage B cell maturation blocked

decreased dendritic cell number ( J:91043 )

• proportion of dendritic cells in spleen 50% of controls but proportion as expected in thymus

• single (+) CD4 dendritic cells reduced to about 10% of control levels in the spleen

absent plasma cells ( J:42683 )

• no plasma cells in spleen or lamina propria

increased lymphocyte cell number ( J:42683 )

• normal lymphocyte distribution at 4-5 weeks of age

• expanded numbers of T and B lymphocytes at 10-15 weeks of age

abnormal spleen morphology ( J:42683 )

enlarged spleen ( J:42683 )

• spleen enlarged 3-5X by 10-15 weeks of age

absent spleen germinal center ( J:42683 )

• absent germinal centers in B cell follicles of spleen

decreased immunoglobulin level ( J:42683 )

• all immunoglobulin classes reduced by 99% or more

growth/size/body

enlarged spleen ( J:42683 )

• spleen enlarged 3-5X by 10-15 weeks of age

Genotype
MGI:3584110

hm3

• Allelic Composition: Irf4^tm1Mak/Irf4^tm1Mak
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

decreased plasmacytoid dendritic cell number ( J:97716 )

• plasmacytoid dendritic cells in spleen reduced to half of control levels

increased susceptibility to bacterial infection ( J:81744 )

• Leishmania numbers increase slowly after infection

• T cell numbers drop late in the infection

hematopoietic system

decreased plasmacytoid dendritic cell number ( J:97716 )

• plasmacytoid dendritic cells in spleen reduced to half of control levels

Genotype
MGI:5529093

cx4

• Allelic Composition: Col1a1^{tm1(tetO-Irf4)Sing}/Col1a1^{tm1(tetO-Irf4)Sing}; Gt(ROSA)26Sor^{tm1(rtTA*M2)Jae}/Gt(ROSA)26Sor⁺; Irf4^tm1Mak/Irf4⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6

hematopoietic system

abnormal class switch recombination ( J:203903 )

• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination

abnormal plasma cell differentiation ( J:203903 )

• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination

immune system

abnormal class switch recombination ( J:203903 )

• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination

abnormal plasma cell differentiation ( J:203903 )

• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination

Genotype
MGI:5529094

cx5

• Allelic Composition: Col1a1^{tm1(tetO-Irf4)Sing}/Col1a1^{tm1(tetO-Irf4)Sing}; Gt(ROSA)26Sor^{tm1(rtTA*M2)Jae}/Gt(ROSA)26Sor⁺; Irf4^tm1Mak/Irf4^tm1Mak
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6

hematopoietic system

abnormal class switch recombination ( J:203903 )

• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination but not as severe as in mice heterozygous for Irf4^tm1Mak

abnormal plasma cell differentiation ( J:203903 )

• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination but not as severe as in mice heterozygous for Irf4^tm1Mak

immune system

abnormal class switch recombination ( J:203903 )

• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination but not as severe as in mice heterozygous for Irf4^tm1Mak

abnormal plasma cell differentiation ( J:203903 )

• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination but not as severe as in mice heterozygous for Irf4^tm1Mak

Genotype
MGI:3584112

cx6

• Allelic Composition: Irf8^tm1Hor/Irf8^tm1Hor; Irf4^tm1Mak/Irf4^tm1Mak
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

abnormal B cell differentiation ( J:84577 )

arrested B cell differentiation ( J:84577 )

• B cell development blocked in bone marrow at the pre-B cell stage

decreased dendritic cell number ( J:97716 )

• numbers of double negative dendritic cells reduced in spleen to half of control levels and very few found in thymus

decreased plasmacytoid dendritic cell number ( J:97716 )

• plasmacytoid dendritic cells in spleen reduced considerably

decreased lymphocyte cell number ( J:84577 )

absent B cells ( J:84577 )

• peripheral B cells lacking

decreased T cell number ( J:84577 )

• reduced numbers of both types of single positive T cells

abnormal pre-B cell morphology ( J:84577 )

• display cytoplasmic mu heavy chain and high levels of preBCR

• pre-B cells held up is S and G2 phase of cell cycle

increased pre-B cell number ( J:84577 )

• 5 fold increase in numbers

decreased IgM level ( J:84577 )

• soluble IgM lacking

hematopoietic system

abnormal B cell differentiation ( J:84577 )

arrested B cell differentiation ( J:84577 )

• B cell development blocked in bone marrow at the pre-B cell stage

decreased dendritic cell number ( J:97716 )

• numbers of double negative dendritic cells reduced in spleen to half of control levels and very few found in thymus

decreased plasmacytoid dendritic cell number ( J:97716 )

• plasmacytoid dendritic cells in spleen reduced considerably

decreased lymphocyte cell number ( J:84577 )

absent B cells ( J:84577 )

• peripheral B cells lacking

decreased T cell number ( J:84577 )

• reduced numbers of both types of single positive T cells

abnormal pre-B cell morphology ( J:84577 )

• display cytoplasmic mu heavy chain and high levels of preBCR

• pre-B cells held up is S and G2 phase of cell cycle

increased pre-B cell number ( J:84577 )

• 5 fold increase in numbers

decreased IgM level ( J:84577 )

• soluble IgM lacking